Volume : 12, Issue : 06, June – 2025
Title:
META ANALYSIS OF PREVALANCE, COMORBIDITIES & TREATMENT IN VITILIGO
Authors :
Rangam Chariitha*, B. Hanumanthu, V. Vijay Kumar, K. Karthik Reddy, K. Sushma,DrT.Mangilal
Abstract :
Vitiligo is a chronic autoimmune skin disorder characterized by the loss of melanin pigment, resulting in white patches on the skin. This systematic review aimed to evaluate the prevalence, associated comorbidities, and treatment approaches of vitiligo. Data from 22 published articles encompassing 5,794 patients were analysed, with findings showing a higher incidence in individuals below 20 years of age (85.8%) and a slight female predominance (51.89%). Comorbidities were common, with thyroid disorders (25.2%), diabetes mellitus (13.88%), and psychiatric conditions like depression (8.0%) being most frequent. Treatment modalities included topical corticosteroids, calcineurin inhibitors, phototherapy (NB-UVB and PUVA), laser therapy, and surgical techniques like grafting and micropigmentation. Newer approaches like JAK inhibitors and antioxidants are under exploration. The study emphasizes the systemic nature of vitiligo and the necessity of a multidisciplinary management approach, including dermatological, endocrine, and psychological care, to enhance patient outcomes and quality of life.
Keywords
Vitiligo, Autoimmune disorder, Skin pigmentation, Comorbidities, Thyroid disorders, Diabetes mellitus, Anxiety, Depression, Hypertension, Antioxidants, Systematic review, Multidisciplinary management.
Cite This Article:
Please cite this article in press Rangam Chariitha et al., A Meta Analysis Of Prevalance, Comorbidities & Treatment In Vitiligo., Indo Am. J. P. Sci, 2025; 12(07).
Number of Downloads : 10
References:
1.https://my.clevelandclinic.org/health/diseases/12419-vitiligo
2.Emre et al., 2024 Vitiligo Associated With Sarcoidosis: Case Based Review Archives of Clinical Trials 4(1), 1-5.
3.Delin Ran et al., 2019 Genetics of psoriasis: a basis for precision medicine Precision clinical medicine 2(2),120-130.
4.Ming-Chen Sun et al., 2020 Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo 3267-3279.
5.Emine et al., 2022 Vitiligo: Pathogenesis, Clinical Features, and Treatment Etiology and recent advances in treatment 276
6.Abu et al., 2010 Current remedies for vitiligo Autoimmunity Reviews 9(7):516-20
7.Yuhui et al., 2016 The Prevalence of Vitiligo: A Meta-Analysis PLoS ONE 11(9): e0163806.
8.Mohammad Afkhami et al., 2014 Prevalence of vitiligo among type 2 diabetic patients in an Iranian population International Journal of Dermatology, 53:956–958
9.Morales et al., 2016; aceptado el 10 Impacto del vitíligo en la calidad de vida pgno:2-5
10.Jakub Sawicki et al., 2012 Vitiligo and Associated Autoimmune Disease: Retrospective Review of 300 Patients Journal of Cutaneous Medicine and Surgery, 16 (4): pp 261-266
11.Aisha et al., 2018 Comorbidities in vitiligo: comprehensive review, International Journal of Dermatology, 1-6
12.Porter et al., 1987. Response to cosmetic disfigurement: patients with vitiligo. Cutis. 1987;39(6):493-494.
13.Delfino et al., 1988 Personality profiles in patients with alopecia areata. Annal Ital Dermatol, 42(3):271-275.
14.Zettinig et al., 2002 Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume
15.Reza et al., 2020 Vitiligo and Rise in Blood Pressure – a Case– Control Study in a Referral Dermatology Clinic in Southern Iran Clinical, Cosmetic and Investigational Dermatology :13 425–430
16.Yamamoto et al., 2011 Application of a two-question screening instrument to detect depressive symptoms in patients with vitiligo: A pilot study. J Am Acad Dermatol. 64(5):69-70.
17.Kakourou et al., 2005 GP. Increased prevalence of chronic autoimmune (Hashimoto’s) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 53:220–3.
18.K. V. T. Gopal et al., 2014 Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients Indian Dermatology Online Journal 5:456-459.
19.Karia B Karia 1, Avinash De Sousa 1, Nilesh Shah 1, Sushma Sonavane 1, Anup Bharati 1 Psychiatric morbidity and quality of life in skin diseases: A comparison of alopecia areata and psoriasis
20.Alshahwan et al., 2015 The prevalence of anxiety and depression in Arab dermatology patients. J Cutan Med Surg. 2015;19(3):297-303.
21.Altaf H et al., 2010 Evaluation of thyroid function and presence of anti-thyroid peroxidase antibodies in patients with vitiligo. Egyptian Dermatol Online J. 6:1–13.
22.Nunes et al., 2011 vitiligo epidemiological and the association with thyroid disease Anais Brasileiros de Dermatologia, 86(2), 241-8.
23.Biswas et al., 2015 A study on association between vitiligo and thyroid dysfunction. IOSR-Journal of Dental and Medical Sciences; 14: 34-7.
24.Ramakrishna P, Rajni T. Psychiatric morbidity and quality of life in vitiligo patients. Indian Journal of Psychol Medicine, 2014;36(3):302.
25.Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. British Journal of Dermatology, 2000; 143:983–991.
26.Ajose et al.2013 Quantification and comparison of psychiatric distress in African patients with albinism and vitiligo: a 5-year prospective study. Journal of European academy of Dermatol Venereol ;28(7):925-932.
27.Sharma et al., 2001 Psychiatric morbidity in psoriasis and vitiligo: A comparative study. Journal of Dermatol. ;28(8):419-423.
28.karelson et al., 2013Quality of life and emotional state in vitiligo in an Estonian sample: Comparison with psoriasis and healthy controls. Acta Dermato Venereologica 93(4):446-450.
29.Sampogna F, Picardi A, Chren M et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med. 2004;66(4):620-624.